FUT1 antibodies target the α-1.2-fucosyltransferase enzyme encoded by the FUT1 gene, which plays a critical role in synthesizing H antigen structures on cell surfaces. The H antigen serves as the foundational precursor for the ABO blood group system, where specific glycosyltransferases modify it to produce A or B antigens. FUT1 is primarily expressed in epithelial and endothelial cells, contributing to the formation of H-type 2 antigens (on glycolipids or glycoproteins), whereas FUT2 generates H-type 1 antigens in secretions. Antibodies against FUT1 are valuable tools for studying H antigen distribution in tissues and its biological roles, including cell adhesion, microbial interactions, and immune responses.
Dysregulation of FUT1 expression has been linked to pathological conditions. For instance, reduced H antigen levels due to FUT1 mutations are associated with rare blood group phenotypes like the "Bombay phenotype," where individuals lack ABO antigens. Conversely, aberrant overexpression of FUT1 in certain cancers (e.g., gastric, colorectal) correlates with tumor progression and metastasis, likely through enhanced cell-matrix interactions. FUT1 antibodies are thus employed in diagnostics to identify H antigen deficiencies or anomalies, as well as in research to explore cancer biomarkers or host-pathogen interactions (e.g., norovirus binding to H antigens). These antibodies are commonly used in techniques like flow cytometry, immunohistochemistry, and Western blotting to map H antigen expression patterns in health and disease.